Results 111 to 120 of about 11,727 (181)

A case report of mixed-phenotype acute leukemia with atypical BCR::ABL1 e13a3 fusion gene. [PDF]

Medicine (Baltimore)
Zhou Y, Liu M, Zhao Y, Zhang R, Guo Q, Wang Z, Nie Y, Yang J, Shi M, Shi M.   +9 more
europepmc   +1 more source

Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib. [PDF]

Sci Signal
Muratcioglu S, Eide CA, Hung CL, Gorday K, Sumpena E, Zuo W, Groves JT, Druker BJ, Kuriyan J.   +8 more
europepmc   +1 more source

LIN28A-Dependent Kinome and Phosphoproteome Reprogramming Promotes Imatinib Resistance. [PDF]

Mol Cell Proteomics
Hovey OFJ, Frederick MI, Quach QM, Kakadia JH, Wu A, Yang K, Wu T, Ruan X, Kaneko T, Voss C, Heinemann IU, Li SSC.   +11 more
europepmc   +1 more source

Molecular genetic characteristics and clinical significance of childhood acute lymphoblastic leukemia. [PDF]

Front Pediatr
Zhu Z, Yan J.
europepmc   +1 more source

Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines. [PDF]

J Cell Mol Med
Okabe S, Yoshizawa S, Arai Y, Gotoh A, Akahane D.   +4 more
europepmc   +1 more source

Advances in Targeting BCR-ABL^T315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules. [PDF]

Molecules
Tuzikiewicz A, Wawrzyniak W, Kutner A, Żołek T.   +3 more
europepmc   +1 more source

Streptomyces koyangensis L-asparaginase: computational prediction of dual-mechanism BCL-2 interaction in acute lymphoblastic leukemia. [PDF]

Sci Rep
Solanki G, Prajapati C, Gadhvi R, Kamble L, Sharma MC, Hajare ST.   +5 more
europepmc   +1 more source

Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia. [PDF]

Leukemia
Houtman AH, Arfeuille C, Strullu M, Baruchel A, Cavé H, Caye-Eude A.   +5 more
europepmc   +1 more source

From the bench of molecular understanding to the bedside of optimal therapy for <i>BCR</i>::<i>ABL1</i> and ABL-class acute lymphoblastic leukemia in children and adolescents. [PDF]

EJC Paediatr Oncol
Tasian SK, Boer JM, den Boer ML.
europepmc   +1 more source

Advantages of PROTACs in achieving selective degradation of homologous protein families. [PDF]

Beilstein J Org Chem
Yang L, Mao X, Zhang J, Shu J, Huang W, Dong X, Chen Y, Wu M.   +7 more
europepmc   +1 more source